The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE DEVELOPMENT OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS POST ECTRIMS 2024 Paris, 23 September 2024, 5.45pm CET AB Science SA (Euronext - ...

Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a ...

The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...

Qualcomm (NASDAQ:QCOM) – Apollo Global Management has reportedly offered up to $5 billion to invest in Intel, according to ...

Pakistan PM Shehbaz to raise Kashmir, Palestine, Islamophobia issues at UNGA Pakistan Prime Minister Shehbaz Sharif is set to address the United Nations General Assembly on September 27. He will ...

Shares in Neurocrine Biosciences took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors. The 19% after-market selloff ...

Bristol-Myers Squibb has upgraded a long-running alliance with Prothena in Alzheimer’s disease, taking an option on a tau protein-targeting antibody in early-stage clinical development.

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in three decades—and the company also sees potential in Alzheimer’s psychosis ...

Ryan Routh, aged 58, allegedly attempted to assassinate former President Donald Trump at his Florida golf course by aiming a rifle through the tree line. He had earlier written a letter offering $ ...

"Every day has been a nightmare," victim Lutalo Henderson's sister told the Daily News in an exclusive interview. "We all loved him." ...

Trump and the Republican National Committee he controls decided to share get-out-the-vote duties in the most competitive states with groups such as the one supported by billionaire Elon Musk.